Literature DB >> 23859553

In vivo application of beta amyloid oligomers: a simple tool to evaluate mechanisms of action and new therapeutic approaches.

Claudia Balducci, Gianluigi Forloni1.   

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cerebral accumulation of extracellular amyloid β (Aβ) and neurofibrillary tangles made of hyperphosphorylated tau protein, two main lesions which appear sequentially during the disease progression. In the last decade numerous studies have proposed small soluble aggregates of Aβ, known as oligomers, as the species responsible for synaptic dysfunction, memory loss and neurodegeneration typical of AD. In vitro and in vivo experiments have identified Aβ oligomers as the elements that can alter synaptic function by a reversible mechanism, which gradually becomes permanent when exposure is continuous. Here we show that intracerebroventricular (ICV) injection in mice of a solution containing specifically Aβ1-42 oligomers substantially affects their memory when tested in the novel object recognition task. This acute mouse model enabled us to distinguish whether oligomers were affecting specific phases of the memory processing. A single injection of Aβ1-42 oligomers before memory consolidation abolished information processing, leading to memory impairment, whereas no such effects were observed when the injection was done once the information had been processed, indicating that the oligomers affect memory consolidation rather than retrieval. Beside Aβ1-42, Aβ1-40 oligomers also impaired memory, and both isoforms were antagonized by the anti-Aβ4G8 monoclonal antibody. This simple and reliable paradigm is useful to investigate the mechanisms through which Aβ oligomers interfere with neuronal processes and to test the efficacy of new therapeutic approaches specifically against these species. We tested several molecules by direct coincubation with Aβ oligomers, ICV injections preceding Aβ oligomers, and the systemic treatment with drugs that cross the blood brain barrier. We also examined the proposed involvement of cellular prion protein as a mediator of the oligomer-induced memory impairment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23859553     DOI: 10.2174/13816128113199990497

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  22 in total

Review 1.  APP/Aβ structural diversity and Alzheimer's disease pathogenesis.

Authors:  Alex E Roher; Tyler A Kokjohn; Steven G Clarke; Michael R Sierks; Chera L Maarouf; Geidy E Serrano; Marwan S Sabbagh; Thomas G Beach
Journal:  Neurochem Int       Date:  2017-08-12       Impact factor: 3.921

Review 2.  Rodent models for Alzheimer's disease drug discovery.

Authors:  Daniela Puzzo; Walter Gulisano; Agostino Palmeri; Ottavio Arancio
Journal:  Expert Opin Drug Discov       Date:  2015-04-30       Impact factor: 6.098

3.  Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model.

Authors:  Zhong-Hao Zhang; Qiu-Yan Wu; Rui Zheng; Chen Chen; Yao Chen; Qiong Liu; Peter R Hoffmann; Jia-Zuan Ni; Guo-Li Song
Journal:  J Neurosci       Date:  2017-01-30       Impact factor: 6.167

4.  Differential effects of ischemic vascular disease and Alzheimer's disease on brain atrophy and cognition.

Authors:  Ling Zheng; Harry V Vinters; Wendy J Mack; Michael W Weiner; Helena C Chui
Journal:  J Cereb Blood Flow Metab       Date:  2016-01       Impact factor: 6.200

5.  Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's Disease.

Authors:  Gilbert M Rishton; Gary C Look; Zhi-Jie Ni; Jason Zhang; Yingcai Wang; Yaodong Huang; Xiaodong Wu; Nicholas J Izzo; Kelsie M LaBarbera; Colleen S Limegrover; Courtney Rehak; Raymond Yurko; Susan M Catalano
Journal:  ACS Med Chem Lett       Date:  2021-08-09       Impact factor: 4.632

6.  Modeling Amyloid-β42 Toxicity and Neurodegeneration in Adult Zebrafish Brain.

Authors:  Prabesh Bhattarai; Alvin Kuriakose Thomas; Mehmet Ilyas Cosacak; Christos Papadimitriou; Violeta Mashkaryan; Yixin Zhang; Caghan Kizil
Journal:  J Vis Exp       Date:  2017-10-25       Impact factor: 1.355

7.  Periodic Variation of AAK1 in an Aβ1-42-Induced Mouse Model of Alzheimer's Disease.

Authors:  Xue Fu; Meiling Ke; Weihua Yu; Xia Wang; Qian Xiao; Min Gu; Yang Lü
Journal:  J Mol Neurosci       Date:  2018-05-17       Impact factor: 3.444

8.  Poly-N-methylated Aβ-Peptide C-Terminal fragments (MEPTIDES) reverse the deleterious effects of amyloid-β in rats.

Authors:  Siya G Sibiya; Musa V Mbandla; Thavi Govender; Adeola Shobo; William M U Daniels
Journal:  Metab Brain Dis       Date:  2017-10-09       Impact factor: 3.584

9.  Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy.

Authors:  Ilya Chumakov; Serguei Nabirotchkin; Nathalie Cholet; Aude Milet; Aurélie Boucard; Damien Toulorge; Yannick Pereira; Esther Graudens; Sory Traoré; Julie Foucquier; Mickael Guedj; Emmanuel Vial; Noëlle Callizot; Rémy Steinschneider; Tangui Maurice; Viviane Bertrand; Catherine Scart-Grès; Rodolphe Hajj; Daniel Cohen
Journal:  Sci Rep       Date:  2015-01-08       Impact factor: 4.379

10.  Transnasal delivery of human A-beta peptides elicits impaired learning and memory performance in wild type mice.

Authors:  Kristina Endres; Sven Reinhardt; Anastasia Geladaris; Julia Knies; Marcus Grimm; Tobias Hartmann; Ulrich Schmitt
Journal:  BMC Neurosci       Date:  2016-07-04       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.